How CAR T Therapies Stack Up Against Standard of Care for LBCL Across Lines of Treatment, Cost Perspectives
The PINC AI™ Applied Sciences (PAS) team is dedicated to furthering oncology research and recently presented their findings at the 64th American Society of Hematology Annual Meeting and Exposition titled "Hospital costs and healthcare resource utilization (HRU) for chimeric antigen (CAR) T-cell therapy and stem cell transplant (SCT) in patients with large B-cell lymphoma (LBCL) in the United States (US)."
The team’s research found in adult patients with large B-cell lymphomas (LBCL), the total cost of CAR T-cell therapy was higher than that of hematopoietic stem cell transplant (HSCT) procedure, which was primarily driven by the pharmacy cost. From a provider perspective, the non-pharmacy cost and healthcare resource utilization were both lower for CAR T-cell than for HSCT procedure in patients with LBCL.
This research was featured in a recent article in the American Journal of Managed Care.®
